Dr. Ruth Casey and Dr. Christina Pamporaki offer valuable information on pediatric pheo/para, while also discussing the recent release of the consensus statement.
We would also like to extend a special thank you to Novartis, who made this educational webinar possible!
Timings and questions are as follows:
48:31 – Q1: How do you manage incidentally found tumors on an asymptomatic SDHB patient if the tumor is not easily resectable?
50:58 – Q2: I recall seeing a new drug that is potentially available to treat these tumors. (In reference to Belzutifan)
52:13 – Q3: In patients with MEN2 who are found to have an adrenal tumor suspected of being clinically silent pheochromocytoma, and a normal biochemistry, is adrenal blockage necessary?
55:26 – Q4: Can you please clarify how knowing the somatic variant driving a PPGL in a germline negative patient impact management?
57:58 – Q5: I as a parent didn’t have my tumor tested and was only tested via blood. Would I want to be tested again in case there was another variant? Or is this something that I should do every few years?
1:00:07 – Q6: How do we address the psychological impact of a diagnosis such as a pheochromocytoma or a paraganglioma in children and their families?